Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionWells Fargo & Company/mn
Latest Disclosed Ownership89,406 shares
Latest Disclosed Value $ 2,656,251
Wells Fargo & Company/mn ownership in TVTX / Travere Therapeutics, Inc.

On May 11, 2026 - Wells Fargo & Company/mn filed a 13F-HR form disclosing ownership of 89,406 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $2,656,252 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 158,834 shares of Travere Therapeutics, Inc.. This represents a change in shares of -43.71% during the quarter. The current value of the position is $4,041,151 USD.

Wells Fargo & Company/mn has a history of taking positions in derivatives of the underlying security (TVTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

TVTX / Travere Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 89,406 -69,428 -43.71 2,656 -56.24 0.0003
2026-02-13 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 158,834 84,151 112.68 6,069 240.19 0.0011
2025-11-13 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 74,683 5,863 8.52 1,785 75.25 0.0003
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 68,820 2,753 4.17 1,019 -13.95 0.0002
2025-05-13 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 66,067 8,619 15.00 1,184 18.30 0.0003
2025-02-13 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 57,448 17,716 44.59 1,001 80.18 0.0002
2024-11-13 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 39,732 -2,808 -6.60 556 59.03 0.0001
2024-08-13 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 42,540 8,433 24.73 350 33.21 0.0001
2024-05-10 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 34,107 1,649 5.08 263 -9.97 0.0001
2024-02-09 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 32,458 -63,372 -66.13 292 -66.00 0.0001
2023-11-13 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 95,830 -27,066 -22.02 857 -54.64 0.0003
2023-08-15 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 122,896 52,518 74.62 1,888 19.28 0.0005
2023-05-12 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 70,378 67,153 2,082.26 1,583 2,261.19 0.0005
2023-02-13 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 3,225 -2,123 -39.70 68 -48.85 0.0000
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 5,348 1,083 25.39 131 27.18 0.0000
2022-08-12 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 4,265 -38,265 -89.97 103 -90.60 0.0000
2022-05-16 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 42,530 -17,895 -29.62 1,096 -41.58 0.0003
2022-02-14 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 60,425 14,319 31.06 1,876 67.80 0.0005
2021-11-15 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 46,106 -164,520 -78.11 1,118 -63.62 0.0002
2021-08-16 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 210,626 59,518 39.39 3,073 -18.57 0.0007
2021-05-13 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 151,108 38,961 34.74 3,774 23.49 0.0009
2021-02-09 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 112,147 14,948 15.38 3,056 70.35 0.0007
2020-11-05 2020-09-30 13F RETROPHIN COM 761299106 97,199 6,947 7.70 1,794 -2.61 0.0005
2020-08-13 2020-06-30 13F RETROPHIN COM 761299106 90,252 67,390 294.77 1,842 453.15 0.0005
2020-05-14 2020-03-31 13F RETROPHIN COM 761299106 22,862 -37,637 -62.21 333 -61.23 0.0001
2020-02-14 2019-12-31 13F RETROPHIN COM 761299106 60,499 36,680 153.99 859 211.23 0.0002
2019-11-12 2019-09-30 13F RETROPHIN COM 761299106 23,819 1,276 5.66 276 -39.07 0.0001
2019-08-06 2019-06-30 13F RETROPHIN COM 761299106 22,543 -45,805 -67.02 453 -70.72 0.0001
2019-05-10 2019-03-31 13F RETROPHIN COM 761299106 68,348 -822 -1.19 1,547 -1.21 0.0005
2019-02-11 2018-12-31 13F RETROPHIN COM 761299106 69,170 -41,415 -37.45 1,566 -50.71 0.0005
2018-11-02 2018-09-30 13F RETROPHIN COM 761299106 110,585 15,335 16.10 3,177 22.33 0.0009
2018-08-01 2018-06-30 13F RETROPHIN COM 761299106 95,250 19,216 25.27 2,597 52.67 0.0008
2018-05-02 2018-03-31 13F RETROPHIN COM 761299106 76,034 -954 -1.24 1,701 4.87 0.0005
2018-02-08 2017-12-31 13F RETROPHIN COM 761299106 76,988 18,314 31.21 1,622 11.02 0.0005
2017-11-09 2017-09-30 13F RETROPHIN COM 761299106 58,674 19,163 48.50 1,461 90.48 0.0005
2017-08-10 2017-06-30 13F RETROPHIN COM 761299106 39,511 -11,274 -22.20 767 -18.23 0.0002
2017-04-28 2017-03-31 13F RETROPHIN COM 761299106 50,785 5,763 12.80 938 10.09 0.0003
2017-02-01 2016-12-31 13F RETROPHIN COM 761299106 45,022 7,292 19.33 852 0.95 0.0003
2016-10-31 2016-09-30 13F RETROPHIN COM 761299106 37,730 9,092 31.75 844 65.49 0.0003
2016-08-11 2016-06-30 13F RETROPHIN COM 761299106 28,638 -1,450 -4.82 510 24.39 0.0002
2016-05-16 2016-03-31 13F RETROPHIN COM 761299106 30,088 448 1.51 410 -28.20 0.0002
2016-02-09 2015-12-31 13F RETROPHIN COM 761299106 29,640 -314,529 -91.39 571 -91.81 0.0002
2015-11-13 2015-09-30 13F RETROPHIN COM 761299106 344,169 24,744 7.75 6,972 -34.15 0.0029
2015-08-14 2015-06-30 13F RETROPHIN COM 761299106 319,425 318,292 28,092.85 10,588 39,114.81 0.0041
2015-05-12 2015-03-31 13F/A-1 RETROPHIN COM 761299106 1,133 146 14.79 27 125.00 0.0000
2015-05-12 2015-03-31 13F RETROPHIN COM 761299106 1,133 27
2015-02-11 2014-12-31 13F RETROPHIN COM 761299106 987 -692 -41.22 12 -20.00 0.0000
2014-11-06 2014-09-30 13F RETROPHIN COM 761299106 1,679 166 10.97 15 -16.67 0.0000
2014-08-29 2014-06-30 13F/A-1 RETROPHIN COM 761299106 1,513 1,513 18 0.0000
2014-08-12 2014-06-30 13F RETROPHIN COM 761299106 1,513 18 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F TRAVERE THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-11-13 2025-09-30 13F TRAVERE THERAPEUTICS COM Call 168,000 0.00 4,015 61.50 n/a n/a n/a
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM Call 168,000 0.00 2,486 -17.41 n/a n/a n/a
2025-05-13 2025-03-31 13F TRAVERE THERAPEUTICS COM Call 168,000 0.00 3,011 2.87 n/a n/a n/a
2025-02-13 2024-12-31 13F TRAVERE THERAPEUTICS COM Call 168,000 0.00 2,927 24.51 n/a n/a n/a
2024-11-13 2024-09-30 13F TRAVERE THERAPEUTICS COM Call 168,000 2,350 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.